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. However, more intensive treatments, including high doses of aracytine and BM transplantation during complete remission, may significantly improve the survival rate of patients with de novo AMKL. None of the current biological features -that is, WBC, platelet counts or Hb level at with diagnosis, age, etc. -seem associated with the fraction of 'good responders' to intensive treatments. It would be of interest to investigate the role of the recurrent t(1;22) translocation in response to therapy. It is worth noting that long-term survivors could be found among patients with t(1;22)-positive AMKL, even those treated with 'standard' AML therapy. 8 The presently described reliable assay for the detection and monitoring of the OTT-MAL fusion transcripts is of value in assessing the therapeutic response, the presence of residual cells in the autologous BM prior to BM transplantation and the choice of the best drugs combinations for the treatment of t(1;22) AMKL. It is also a suitable complement of cytogenetic search of the t(1;22)(p13;q13) translocation in AMKL. 2,3 Despite normal transcription and intracellular synthesis, we previously showed 4 that this low expression is accounted for by a defective assembly of the BCR chains resulting in the presence of unprocessed m chains. To gain insight into the mechanism accounting for this low expression, we aimed to define the cell compartment where the BCR retention occurs. In addition, as the lack of costimulatory molecules characteristic of CLL B cells can be at least partially restored upon CD40 ligand (CD40L) stimulation, 5 we investigate the effect of such stimulation on the defective IgM and CD79b intracellular assembly and surface expression.
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B cells from four CLL patients and three normal controls were analysed by flow cytometry for surface and intracellular IgM and CD79b expression and by confocal microscopy for the intracellular IgM localization, assembly with CD79b and transport to the cell surface. A CD40L+IL-4 stimulation of CLL B cells was performed, to determine whether it could revert the defective assembly and surface expression. Before stimulation, a consistent low expression of surface IgM and CD79b was observed in CLL patients, which contrasts with normal subjects (Figure 1a Given the key role of CD79b in BCR surface expression, its defective transport could account for low surface IgM expression.
CD79b is transcribed in the form of long transcripts coding for the complete protein and short transcripts (DCD79b), which are depleted of the extramembrane domain. However, DCD79b transcripts could not account for the low surface expression, since the CD79b/ DCD79b ratio as assessed by reverse transcriptase polymerase chain reaction (RT-PCR) did not display important differences between normal and CLL B cells before stimulation Figure 1 CLL B cells surface expression and CD79b transcripts before and after stimulation with CD40L+IL-4. (a and b) Flow-cytometric analysis of normal or CLL B cells before and after stimulation with CD40L+IL-4. Normal B cells purified through negative depletion or peripheral blood mononuclear cells from CLL patients were stained for IgM, CD79b, CD80, CD86 surface expression, before or after a 6-day culture with CD40L (1 mg/ml)+IL-4 (1000 U/ml). The data were reproduced in independent experiments from three normal controls and four CLL patients. The numbers in the upper right corner of each panel are the percentage of IgM+/CD79b+, IgM+/CD80+ or IgM+/CD86+ cells, respectively. (c) RT-PCR analysis of CD79b long (709 bp) and DCD79b short (397 bp) transcripts in controls (lanes a-c) and CLL (lanes d-g) before and after CD40L+IL-4 stimulation (indicated by asterisk). The long to short transcripts ratio was calculated in the linear step of the reaction. MW, molecular weight marker. 1.2570.16 and 0.6970.32, respectively) . This is consistent with results reported by Cragg et al 6 showing that the level of DCD79b transcripts does not impair surface BCR expression. Overall, our results demonstrate that CD40L succeeded to induce a moderate upregulation of surface IgM in CLL B cells and almost no change of surface CD79b expression despite an upregulation of costimulatory molecules.
Correspondence
The cellular compartments involved in BCR retention, and the effect of CD40L+IL-4 stimulation on BCR assembly and transport, were then investigated by confocal microscopy analysis after simultaneous staining of IgM and calnexin, a chaperon protein of the endoplasmic reticulum (ER) or golgin, a protein characteristic of the Golgi compartment, or CD79b. While normal B cells showed two separate stainings for IgM (red) and calnexin (green), in CLL B cells IgM colocalized with calnexin as shown by the yellow merged image ( Figure 2a) ; this was still observed after stimulation. As for Golgi compartment, similar colocalization of IgM and golgin was observed for normal and CLL B cells (Figure 2b ). However, in contrast to normal B cells, IgM and CD79b did very poorly colocalize (separate red and green stainings) in CLL B cells (Figure 2c ), reflecting a defective assembly that was still evident upon stimulation. These results demonstrate an important IgM retention in the ER of CLL B cells, which might play a critical role in defective assembly of the BCR. In conclusion, upon CD40L+IL-4 stimulation costimulatory molecules could be upregulated, although the defective assembly and transport of the BCR could not be reverted. Impairment of glycosylation mechanisms or ER quality control system does not seem to be involved, since glycoproteins like MHC molecules and CD19 are adequately expressed and others like CD80 and CD86 can be upregulated. It remains to be determined whether the BCR retention in the ER in CLL B cells could be accounted for by: (1) an interaction with an as yet uncharacterized intracellular protein as reported for the K1 protein from human herpesvirus 8 in a B-lymphoma cell line 7 or (2) alterations in IgM motifs leading to defective transport to Golgi as described for CD8a molecule in T cells. Questioning the aim of CML therapy in the era of Imatinib?
Leukemia ( even if long-term survival and long-term toxicity remain unknown. Unfortunately, the International Randomized trial IFN-a/Ara-C vs Imatinib is still at 19 months and no firm conclusion may be drawn on blastic evolution and survival, with the exception of major cytogenetic remission already in favor of Imatinib. In the meantime, many studies involving Imatinib combined with Peg-IFN or lowdose ARA-C started many months ago, but the results of the aboverandomized trial are not yet available. Two of the most convincing advantages of Imatinib were the facility of drug administration and the apparent absence of important side effects. The media amplified these facts and the patients almost always preferred to be treated with Imatinib instead of other transplantation or nontransplantation procedures. Also, the recent randomized trial comparing Imatinib to IFN-a/Ara-C demonstrated that very few patients abandoned Imatinib while over 70% of patients refused to continue IFN+Ara-C. By adding to Imatinib other drugs with different toxicity levels, we cannot be sure of offering a real benefit to our patients, but surely we will increase the toxicity! At the end of the day, I feel that it ought to be emphasized that facts say that the only cure for CML is still allogeneic transplantation. How feasible this is for many patients may be a function of finding a match. We need to reflect on the aim of CML therapy in the era of Imatinib. If the aim is the cure, defined as molecularnegative status after treatment, allogeneic transplantation has successfully provided that. The data on PCR status after IFN-a and Imatinib indicate that only a minority of patients reach PCR negativity, meaning that in cytogenetic remitters also, almost all patients still have minimal residual disease.
Since the problem with allogeneic transplantation is the mortality (30-40% with MUD and about 15-25% for patients with identical sibling donors), a good idea could be to start treatment of newly diagnosed patients with Imatinib. If the patients respond to Imatinib, this treatment should be continued and only high-risk Sokal/Euro patients should receive allogeneic transplantation if they have an HLA-identical donor. If the patients did not respond to Imatinib, conventional therapy, including allogeneic transplantation, should be given.
An alternative and more feasible approach for intermediate highrisk categories could be the protocol as sketched below, proposed 
